Publisher： Bentham Science Publishers
E-ISSN： 1875-5992|9|10|1058-1069
ISSN： 1871-5206
Source： Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol.9, Iss.10, 2009-12, pp. : 1058-1069
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Thalidomide is emerging as a potentially important therapeutic option in the treatment of metastatic prostate cancer. Although the mechanism of action of this agent remains elusive in malignancies of the prostate, recent data has indicated that thalidomide may play a role in inflammation, immunomodulation, and anti-angiogenesis. Lenalidomide (CC-5013), a thalidomide analogue with improved activity and safety profile in certain disease contexts, is in the early stages of development in prostate cancer. This review will provide the current status of the history, mechanism, metabolism, and clinical use of thalidomide in metastatic prostate cancer. It will also describe the mechanism and clinical use of lenalidomide as it pertains to malignancies of the prostate.
Related content
Access to resources
Recommend
Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 11, Iss. 3, 2011-03 ,pp. :
Recent advances revolutionize treatment of metastatic prostate cancer
By Madan Ravi A Arlen Philip M
Future Oncology, Vol. 9, Iss. 8, 2013-08 ,pp. :